Optical pulse labeling studies reveal exogenous seeding slows α-synuclein clearance

Cara Croft,Giavanna Paterno,Ava Vause,Daniel Ryu,Marshall Goodwin,Corey Moran,Pedro Cruz,Benoit Giasson,Todd Golde
DOI: https://doi.org/10.21203/rs.3.rs-1307173/v1
2022-01-28
Abstract:Abstract The accumulation of α-synuclein (α-syn) in intracellular formations known as Lewy bodies (LBs) is associated with several neurodegenerative diseases including Parkinson’s disease and Lewy Body Dementia. There is still limited understanding of how α-syn and the formation of LBs is associated with cellular dysfunction and degeneration in these diseases. To examine the clearance and production dynamics of α-syn we transduced organotypic murine brain slice cultures (BSCs) with recombinant adeno-associated viruses (rAAVs) to express Dendra2-tagged human wild-type and mutant A53T α-syn, with and without the addition of exogenous α-syn fibrillar seeds and tracked them over several weeks in culture using optical pulse labeling. We found that neurons expressing wild-type or mutant A53T human α-syn show similar rates of α-syn turnover even when insoluble, phosphorylated Ser129 α-syn has accumulated. Taken together, this data reveals α-syn aggregation and overexpression, pSer129 α-syn, nor the A53T mutation affect the protein dynamics of α-syn in this system. Prion-type seeding with exogenous α-syn fibrils significantly alters the kinetics of α-syn turnover, resulting in slowed clearance associated with the accumulation of anti-p62 immunoreactivity and Thiazin Red positivity. Prion-type induction of α-syn aggregation results in a more mature LB formation, pointing towards a potential protein clearance deficit in the presence of fibrillar seeds and the ease of this system to explore precise mechanisms underlying these processes. This novel BSC model system facilitates the exploration of α-syn protein dynamics over long-term culture periods. This platform can further be exploited to provide mechanistic insight on what drives this slowing of α-syn turnover and how therapeutics, other genes or different α-syn mutations may affect α-syn protein dynamics.
What problem does this paper attempt to address?